アブストラクト
| Title | 肝細胞癌診療の現状と展望 |
|---|---|
| Subtitle | 今月のテーマ (総論) : 肝細胞癌診療up-to-date |
| Authors | 工藤正俊1) |
| Authors (kana) | |
| Organization | 1)近畿大学医学部消化器内科 |
| Journal | 日本消化器病学会雑誌 |
| Volume | 120 |
| Number | 1 |
| Page | 5-26 |
| Year/Month | 2023 / 1 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 「要旨」: Early-stage肝癌における近年のトピックスの1つとしてSURF試験が挙げられる. SURF試験の結果, RFAと切除の間でRFSやOSに有意差がなかったことから, 2021年版肝癌診療ガイドラインの3cm以下3個以内の肝細胞癌の治療戦略は切除とRFAが横並びとなった. Intermediate-stage肝癌においては, 近年薬物療法とTACEとの組み合わせがTACE単独よりも良好であることが示されるようになってきた. Advanced-stage肝癌については, IMbrave 150試験の結果によりアテゾリズマブ+ベバシズマブが1st lineの第一選択の薬剤となった. |
| Practice | 臨床医学：内科系 |
| Keywords | 肝細胞癌, アテゾリズマブ+ベバシズマブ, ABC conversion therapy, LEN-TACE sequential therapy, Sora-TACE sequential therapy |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Kudo M : Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan : 2021 Update. Liver Cancer 10 ; 167-180 : 2021
- 2) 第24回全国原発性肝癌追跡調査報告, 日本肝癌研究会編, 日本肝癌研究会, 大阪, 2022
- 3) Llovet JM, Ricci S, Mazzaferro V, et al : Sorafenib in adyanced hepatocellular carcinoma. N Engl J Med 359 ; 378-390 : 2008
- 4) Bruix J, Qin S, Merle P, et al : Regorafenib for pa-tients with hepatocellular carcinoma who pro-gressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 ; 56-66 : 2017
- 5) Kudo M, Finn RS, Qin S, et al : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a ran-domised phase 3 non-inferiority trial. Lancet 391 ; 1163-1173 : 2018
残りの100件を表示する
- 6) Zhu AX, Kang YK, Yen CJ, et al : Ramucirumab after sorafenib in patients with advanced hepato-cellular carcinoma and increased alpha-fetoprotein concentrations(REACH-2) : a random-ised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20 ; 282-296 : 2019
- 7) Abou-Alfa GK, Meyer T, Cheng AL, et al : Cabo-zantinib in Patients with Adyanced and Progress-ing Hepatocellular Carcinoma. N Engl J Med 379 ; 54-63 : 2018
- 8) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 ; 1894-1905 : 2020
- 9) Takayama T, Hasegawa K, Izumi N, et al : Sur-gery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma : A Randomized Con-trolled Trial(SURF Trial). Liver Cancer 11 ; 209-218 : 2021
- 10) Chen MS, Li JQ, Zheng Y, et al : A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243 ; 321-328 : 2006
- 11) Huang J, Yan L, Cheng Z, et al : A randomized trial comparing radiofrequency ablation and sur-gical resection for HCC conforming to the Milan criteria. Ann Surg 252 ; 903-912 : 2010
- 12) Feng K, Yan J, Li X, et al : A randomized con-trolled trial of radiofrequency ablation and surgi-cal resection in the treatment of small hepatocel-lular carcinoma. J Hepatol 57 ; 794-802 : 2012
- 13) Hasegawa K, Kokudo N, Makuuchi M, et al : Com-parison of resection and ablation for hepatocellu-lar carcinoma : a cohort study based on a Japa-nese nationwide survey. J Hepatol 58 ; 724-729 : 2013
- 14) Izumi N, Hasegawa K, Nishioka Y, et al : A multi-center randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma(SURF trial). J Clin Oncol 37(suppl 15) ; 4002 : 2019
- 15) Kudo M, Hasegawa K, Kawaguchi Y, et al : A multicenter randomized controlled trial to evalu-ate the efficacy of surgery vs. radiofrequency ab-lation for small hepatocellular carcinoma(SURF trial) : analysis of overall survival. ASCO Annual Meeting, June 4-8, 2021
- 16) Yamashita T, Kawaguchi Y, Kaneko S, et al : A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofre-quency ablation for small hepatocellular carci-noma(SURF-Cohort Trial) : Analysis of overall survival. J Clin Oncol 40(suppl) ; abstract 4095 : 2022
- 17) 日本肝臓学会 : 肝癌診療ガイドライン2021年版, 金原出版, 東京, 2021
- 18) Kudo M, Kawamura Y, Hasegawa K, et al : Man-agement of Hepatocellular Carcinoma in Japan : JSH Consensus Statements and Recommenda-tions 2021 Update. Liver Cancer 10 ; 181-223 : 2021
- 19) Kudo M, Ueshima K, Nakahira S, et al : Adjuvant nivolumab for hepatocellular carcinoma(HCC)af-ter surgical resection(SR)or radiofrequency abla-tion(RFA)(NIVOLVE) : A phase 2 prospective multicenter single-arm trial and exploratory biomarker anlysis 2021. ASCO Annual Meeting, Abstr#4070 : 2021
- 20) Kudo M, Ueshima K, Nakahira S, et al : Final re-sults of adjuvant nivolumab for hepatocellular carcinoma(HCC)after surgical resection(SR)or radiofrequency ablation(RFA)(NIVOLVE) : A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis. ASCO-GI, January 20-22, 2022
- 21) Bruix J, Takayama T, Mazzaferro V, et al : Adju-vant sorafenib for hepatocellular carcinoma after resection or ablation(STORM) : a phase 3, ran-domised, double-blind, placebo-controlled trial. Lancet Oncol 16 ; 1344-1354 : 2015
- 22) Marrero JA, Kulik LM, Sirlin CB, et al : Diagnosis, Staging, and Management of Hepatocellular Car-cinoma : 2018 Practice Guidance by the American Association for the Study of Liver Diseases. He-patology 68 ; 723-750 : 2018
- 23) EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma. J Hepatol 69 ; 182-236 : 2018
- 24) Kokudo N, Takemura N, Hasegawa K, et al : Clini-cal practice guidelines for hepatocellular carci-noma : The Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update. Hepatol Res 49 ; 1109-1113 : 2019
- 25) Kudo M, Izumi N, Kokudo N, et al : Management of hepatocellular carcinoma in Japan : Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology(JSH) 2010 up-dated version. Dig Dis 29 ; 339-364 : 2011
- 26) Kudo M, Matsui O, Izumi N, et al : Transarterial Chemoembolization Failure/Refractoriness : JSH-LCSGJ Criteria 2014 Update. Oncology 87(suppl 1) ; 22-31 : 2014
- 27) Raoul JL, Gilabert M, Piana G : How to define transarterial chemoembolization failure or refrac-toriness : a European perspective. Liver Cancer 3 ; 119-124 : 2014
- 28) Vogel A, Cervantes A, Chau I, et al : Hepatocellu-lar carcinoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(suppl 4) ; iv238-iv255 : 2018
- 29) Management consensus guideline for hepatocel-lular carcinoma : 2016 updated by the Taiwan Liver Cancer Association and the Gastroen-terological Society of Taiwan. J Formos Med As-soc 117 ; 381-403 : 2018
- 30) Cheng AL, Amarapurkar D, Chao Y, et al : Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma : Con-sensus recommendations and review by an Inter-national Expert Panel. Liver Int 34 ; 174-183 : 2014
- 31) Ogasawara S, Chiba T, Ooka Y, et al : Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization. Oncology 87 ; 330-341 : 2014
- 32) Arizumi T, Ueshima K, Chishina H, et al : Valida-tion of the criteria of transcatheter arterial chemoembolization failulre or refractoriness in pa-tients with adyanced hepatocellular carcinoma proposed by the LCSGJ. Oncology 87(suppl 1) ; 32-36 : 2014
- 33) Peck-Radosavljevic M, Kudo M, Raoul J, et al : Outcomes of patients(pts)with hepatocellular carcinoma(HCC)treated with transarterial chemoembolization(TACE) : Global OPTIMIS fi-nal analysis. J Clin Oncol 36(suppl) ; abstr 4018 : 2018
- 34) Peck-Radosavljevic M, Lee HC, Kudo M, et al : Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellu-lar carcinoma who were either ineligible or eligi-ble for transarterial chemoembolization at inclu-sion : Global OPTIMIS exploratory analysis. EASL, April 10-14, Vienna, Austria, Abstr#FRI-494 : 2019
- 35) Kudo M, Han KH, Ye SL, et al : A Changing Para-digm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma : Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 9 ; 245-260 : 2020
- 36) Kudo M, Ueshima K, Chan S, et al : Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function : A Proof-Of-Concept Study. Can-cers 11 ; 1084 : 2019
- 37) Kudo M : A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden : Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 8 ; 299-311 : 2019
- 38) Kawamura Y, Kobayashi M, Shindoh J, et al : (18)F-Fluorodeoxyglucose Uptake in Hepatocellu-lar Carcinoma as a Useful Predictor of an Ex-tremely Rapid Response to Lenvatinib. Liver Cancer 9 ; 84-92 : 2020
- 39) Kawamura Y, Kobayashi M, Shindoh J, et al : Pre-treatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer 9 ; 275-292 : 2020
- 40) Kawamura Y, Kobayashi M, Shindoh J, et al : Lenvatinib-Transarterial Chemoembolization Se-quential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Ad-vanced Hepatocellular Carcinoma. Liver Cancer 9 ; 756-770 : 2020
- 41) Llovet JM, Burroughs A, Bruix J : Hepatocellular carcinoma. Lancet 362 ; 1907-1917 : 2003
- 42) Llovet JM, Villanueva A, Marrero JA, et al : Trial Design and Endpoints in Hepatocellular Carci-noma : AASLD Consensus Conference. Hepatol-ogy 73(suppl 1) ; 158-191 : 2021
- 43) Jain RK : Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy. Sci-ence 307 ; 58-62 : 2005
- 44) Kudo M, Imanaka K, Chida N, et al : Phase III study of sorafenib after transarterial chemoem-bolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47 ; 2117-2127 : 2011
- 45) Lencioni R, Llovet JM, Han G, et al : Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC : The SPACE trial. J Hepatol 64 ; 1090-1098 : 2016
- 46) Meyer T, Fox R, Ma YT, et al : Sorafenib in com-bination with transarterial chemoembolisation in patients with unresectable hepatocellular carci-noma(TACE 2) : a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gas-troenterol Hepatol 2 ; 565-575 : 2017
- 47) Kudo M, Ueshima K, Ikeda M, et al : Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE)plus sorafenib as compared with TACE alone in patients with he-patocellular carcinoma : TACTICS trial. Gut 69 ; 1492-1501 : 2020
- 48) Kudo M, Han G, Finn RS, et al : Brivanib as adju-vant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma : A ran-domized phase III trial. Hepatology 60 ; 1697-1707 : 2014
- 49) Kudo M, Cheng AL, Park JW, et al : Orantinib versus placebo combined with transcatheter ar-terial chemoembolisation in patients with unre-sectable hepatocellular carcinoma(ORIENTAL) : a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 3 ; 37-46 : 2018
- 50) Kudo M, Ueshima K, Ikeda M, et al : Final Resunls of TACTICS : A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoemboliza-tion Alone in Patients with Unresectable Hepato-cellular Carcinoma. Liver Cancer 11 ; 354-367 : 2022
- 51) Llovet JM, Montal R, Villanueva A : Randomized trials and endpoints in adyanced HCC : Role of PFS as a surrogate of survival. J Hepatol 70 ; 1262-1277 : 2019
- 52) Terashima T, Yamashita T, Takata N, et al : Post-progression survival and progression-free sur-vival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatol Res 46 ; 650-656 : 2016
- 53) Kudo M, Montal R, Finn RS, et al : Objective Re-sponse Predicts Survival in Advanced Hepatocel-lular Carcinoma Treated with Systemic Thera-pies. Clin Cancer Res 28 ; 3443-3451 : 2022
- 54) Kudo M : Extremely High Objective Response Rate of Lenvatinib : Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocel-lular Carcinoma. Liver Cancer 7 ; 215-224 : 2018
- 55) Yamashita T, Kudo M, Ikeda K, et al : REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unre-sectable hepatocellular carcinoma : an analysis of Japanese subset. J Gastroenterol 55 ; 113-122 : 2020
- 56) Ueshima K, Nishida N, Hagiwara S, et al : Impact of Baseline ALBI Grade on the Outcomes of He-patocellular Carcinoma Patients Treated with Lenvatinib : A Multicenter Study. Cancers 11 ; 952 : 2019
- 57) Ueshima K, Ishikawa T, Saeki I, et al : Tran-scatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma(TACTICS-L)in Japan : Final analysis. Gastroin-testinal Cancers Symposium(ASCO-GI 2022), San Francisco. January 20-22, 2022
- 58) Kudo M, Ueshima K, Aikata H, et al : Association Between Tumor Response by mRECIST and Overall Survival in Patients With Poorly Differen-tiated HCC in REFLECT Study. Liver Cancer 8 ; abstr O-007 : 2019
- 59) Vogel A, Martinelli E : Updated treatment recom-mendations for hepatocellular carcinoma(HCC)from the ESMO Clinical Practice Guidelines. Ann Oncol 32 ; 801-805 : 2021
- 60) Reig M, Forner A, Rimola J, et al : BCLC strategy for prognosis prediction and treatment recom-mendation : The 2022 update. J Hepatol 76 ; 681-693 : 2022
- 61) Kudo M : Newly developed modified ALBI grade shows better prognostic and predictive value for hepatocellular carcinoma. Liver Cancer 11 ; 1-8 : 2022
- 62) Kudo M : A Novel Treatment Strategy for Pa-tients with Intermediate-Stage HCC Who Are Not Suitable for TACE : Upfront Systemic Ther-apy Followed by Curative Conversion. Liver Can-cer 10 ; 539-544 : 2021
- 63) Cheng AL, Qin S, Ikeda M, et al : Updated effi-cacy and safety data from IMbrave150 : Atezoli-zumab plus bevacizumab vs. sorafenib for unre-sectable hepatocellular carcinoma. J Hepatol 76 ; 862-873 : 2022
- 64) Kudo M, Aoki T, Ueshima K, et al : Achievement of Cancer and Treatment-free Status by Atezoli-zumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization Unsuitabie, Intermediate-stage Hepatocellular Carcinoma : A Multicenter Cohort Study. Liver Cancer(in press)
- 65) Kudo M : Atezolizumab plus Bevacizumab Fol-lowed by Curative Conversion(ABC Conversion)in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer 11 ; 399-406 : 2022
- 66) Kudo M : New treatment paradigm with sys-temic therapy in intermediate-stage hepatocellu-lar carcinoma. Int J Clin Oncol 27 ; 1110-1119 : 2022
- 67) Aoki T, Kubota K, Kubo S, et al : Analysis of Pa-tient Outcome after Non-curative Resection for Hepatocellular Carcinoma Using Nationwide Sur-vey Data in Japan. World J Surg 45 ; 607-614 : 2021
- 68) Cabibbo G, Reig M, Celsa C, et al : First-Line Im-mune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carci-noma : Rationale for Future Trials. Liver Cancer 11 ; 75-84 : 2022
- 69) Osa A, Uenami T, Koyama S, et al : Clinical impli-cations of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3 ; e59125 : 2018
- 70) Cheng AL, Hsu C, Chan SL, et al : Challenges of combination therapy with immune checkpoint in-hibitors for hepatocellular carcinoma. J Hepatol 72 ; 307-319 : 2020
- 71) Chang CJ, Yang YH, Chiu CJ, et al : Targeting tumor-infiltrating Ly6G(+)myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocel-lular carcinoma. Int J Cancer 142 ; 1878-1889 : 2018
- 72) Patnaik A, Swanson KD, Csizmadia E, et al : Cabozantinib Eradicates Advanced Murine Pros-tate Cancer by Activating Antitumor Innate Im-munity. Cancer Discov 7 ; 750-765 : 2017
- 73) Lin YY, Tan CT, Chen CW, et al : Immunomodu-latory Effects of Current Targeted Therapies on Hepatocellular Carcinoma : Implication for the Future of Immunotherapy. Semin Liver Dis 38 ; 379-388 : 2018
- 74) Zhang W, Zhu XD, Sun HC, et al : Depletion of tumor-associated macrophages enhances the ef-fect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16 ; 3420-3430 : 2010
- 75) Yao W, Ba Q, Li X, et al : A Natural CCR2 An-tagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer. EBioMedi-cine 22 ; 58-67 : 2017
- 76) Harding JJ, Nandakumar S, Armenia J, et al : Pro-spective Genotyping of Hepatocellular Carci-noma : Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin Cancer Res 25 ; 2116-2126 : 2019
- 77) Llovet JM, Montal R, Sia D, et al : Molecular therapies and precision medicine for hepatocellu-lar carcinoma. Nat Rev Clin Oncol 15 ; 599-616 : 2018
- 78) Pinyol R, Sia D, Llovet JM : Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Im-munotherapies in HCC. Clin Cancer Res 25 ; 2021-2023 : 2019
- 79) Luke JJ, Bao R, Sweis RF, et al : WNT/β-catenin Pathway Activation Correlates with Immune Ex-clusion across Human Cancers. Clin Cancer Res 25 ; 3074-3083 : 2019
- 80) Yamauchi M, Ono A, Ishikawa A, et al : Tumor Fibroblast Growth Factor Receptor 4 Level Pre-dicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. Clin Transl Gastroenterol 11 ; e00179 : 2020
- 81) Aoki T, Kudo M, Ueshima K, et al : Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Block-ade. Cancers 12 ; 3048 : 2020
- 82) Zhu Y, Yang J, Xu D, et al : Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 68 ; 1653-1666 : 2019
- 83) Lyons YA, Pradeep S, Wu SY, et al : Macrophage depletion through colony stimulating factor 1 re-ceptor pathway blockade overcomes adaptive re-sistance to anti-VEGF therapy. Oncotarget 8 ; 96496-96505 : 2017
- 84) Zopf D, Fichtner I, Bhargava A, et al : Pharma-cologic activity and pharmacokinetics of metabo-lites of regorafenib in preclinical models. Cancer Med 5 ; 3176-3185 : 2016
- 85) Abou-Elkacem L, Arns S, Brix G, et al : Regoraf-enib inhibits growth, angiogenesis, and metasta-sis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 12 ; 1322-1331 : 2013
- 86) Matsushime H, Roussel MF, Ashmun RA, et al : Colony-stimulating factor : regulates novel cy-clins during the G1 phase of the cell cycle. Cell 65 ; 701-713 : 1991
- 87) Wilhelm SM, Dumas J, Adnane L, et al : Regoraf-enib(BAY 73-4506) : a new oral multikinase in-hibitor of angiogenic, stromal and oncogenic re-ceptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129 ; 245-255 : 2011
- 88) Schmieder R, Hoffmann J, Becker M, et al : Re-gorafenib(BAY 73-4506) : antitumor and antime-tastatic activities in preclinical models of colorec-tal cancer. Int J Cancer 135 ; 1487-1496 : 2014
- 89) Takigawa H, Kitadai Y, Shinagawa K, et al : Mul-tikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. Cancer Sci 107 ; 601-608 : 2016
- 90) Chen CW, Ou DL, Hsu CL, et al : FRI-471-Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization. J Hepatol 70 ; e605-e606 : 2019
- 91) Kudo M, Galle PR, Brandi G, et al : Effect of ramu-cirumab on ALBI grade in patients with ad-vanced HCC : Results from REACH and REACH-2. JHEP Rep 3 ; 100215 : 2020
- 92) Kudo M : Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy. Liver Can-cer 10 ; 85-93 : 2021
- 93) Ogasawara S, Ooka Y, Itokawa N, et al : Sequen-tial therapy with sorafenib and regorafenib for adyanced hepatocellular carcinoma : a multicen-ter retrospective study in Japan. Invest New Drugs 38 ; 172-180 : 2020
- 94) Finkelmeier F, Scheiner B, Leyh C, et al : Cabo-zantinib in Advanced Hepatocellular Carcinoma : Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer 10 ; 360-369 : 2021
- 95) Tovoli F, Dadduzio V, De Lorenzo S, et al : Real-Life Clinical Data of Cabozantinib for Unre-sectable Hepatocellular Carcinoma. Liver Cancer 10 ; 370-379 : 2021
- 96) Kudo M, Galle PR, Llovet JM, et al : Ramucirumab in elderly patients, with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int 40 ; 2008-2020 : 2020
- 97) Gordan JD, Kennedy EB, Abou-Alfa GK, et al : Systemic Therapy for Advanced Hepatocellular Carcinoma : ASCO Guideline. J Clin Oncol 38 ; 4317-4345 : 2020
- 98) Peng Z, Fan W, Zhu B, et al : Lenvatinib Com-bined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellu-lar Carcinoma : A Phase III, Randomized Clinical Trial(LAUNCH). J Clin Oncol 2022. doi : 10. 1200/JCO. 22. 00392
- 99) Kudo M, Ueshima K, Chiba Y, et al : Objective Re-sponse by mRECIST Is an Independent Prognos-tic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer 8 ; 505-519 : 2019
- 100) Kudo M, Ueshima K, Yokosuka O, et al : Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma(SILIUS) : a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 3 ; 424-432 : 2018
- 101) Ueshima K, Ogasawara S, Ikeda M, et al : Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carci-noma. Liver Cancer 9 ; 583-595 : 2020
- 102) He M, Li Q, Zou R, et al : Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion : A Ran-domized Clinical Trial. JAMA Oncol 5 ; 953-960 : 2019
- 103) Mazzaferro V, Regalia E, Doci R, et al : Liver transplantation for the treatment of small hepato-cellular carcinomas in patients with cirrhosis. N Engl J Med 334 ; 693-699 : 1996
- 104) Ichida A, Akamatsu N, Hasegawa K : Validation of novel Japanese indication criteria and biomark-ers among living donor liver transplantation re-cipients with hepatocellular carcinoma-a single center retrospective study. Hepatoma Research 6 ; 54 : 2020
- 105) Shimamura T, Akamatsu N, Fujiyoshi M, et al : Expanded living-donor liver transplantation crite-ria for patients with hepatocellular carcinoma based on the Japanese nationwide survey : the 5-5-500 rule-a retrospective study. Transpl Int 32 ; 356-368 : 2019
